Topic: idiopathic pulmonary fibrosis
The ROCK2 inhibitor had a stronger effect on FVC than standard of care, but the lack of detail in the top-line data leave scope for doubts.
Following poor results from Roche and AstraZeneca, Sanofi says it is canning a phase 2 trial in idiopathic pulmonary fibrosis.
After a failed trial in May, AstraZeneca hoped tralokinumab could pass subpopulation tests and make it to the finish line, but it wasn’t meant to be.
California biotech Global Blood Therapeutics is canning its work in idiopathic pulmonary fibrosis (IPF).
Belgian biotech Galapagos has chalked up a positive phase 2a trial for its idiopathic pulmonary fibrosis (IPF) drug GLPG1690, saying it halted the relentless decline in lung function normally seen in patients.
Dermira will take on certain rights to lebrikizumab from Roche.
Shares in the biotech shot up 60% after it posted phase 2 data that suggest it can muscle in on a market fought over by Boehringer and Roche.
Texas startup Lung Therapeutics has got off a $14.3 million series B round as it eyes the cash boost for its trials in fibrosis, lung injury and disease.
Genoa Pharmaceuticals has raised $62 million to take its lead candidate into the clinic.
With pricing pressure mounting in the diabetes space, insulin specialist Novo Nordisk may be looking to wean itself off its core focus with a rumored buyout for Global Blood Therapeutics, a buy that could help boost its own blood disorder business.